Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection
Author:
Publisher
Wiley
Subject
Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1478-3231.2010.02441.x/fullpdf
Reference8 articles.
1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
2. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors;Moore;Ann Oncol,2005
3. Efficacy and saftey of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma; a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009
4. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma;Shao;Cancer,2010
5. Sorafenib;Keating;a review of its use in advanced hepatocellular carcinoma,2009
Cited by 69 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Liver Resection and Transplantation in the Era of Checkpoint Inhibitors;JHEP Reports;2024-08
2. Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy;Anticancer Research;2023-09-29
3. Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus;Frontiers in Pharmacology;2023-09-19
4. The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma;Technology in Cancer Research & Treatment;2023-01
5. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response;Technology in Cancer Research & Treatment;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3